1685 completed, 514 recruiting, 485 unknown, 456 terminated. 2132 Phase 2, 1181 Phase 1, 694 Phase 3, 147 Not applicable, 72 Phase 4.
Follow Cyclophosphamide: new trials by email Literature Review of Cyclophosphamide trials Research Report on Cyclophosphamide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-label Study of GC012F in Rheumatoid Arthritis. LD and GC012F CAR-T Cell Injection, GC012F CAR-T Cell Injection - Rheumatoid Arthritis | Early Phase 1 | Withdrawn | Institute of Hematology & Blood Diseases Hospital, China | 2027-12-01 | 2026-06-10 | |
| AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Recruiting | National Cancer Institute (NCI) | 15 | 2027-07-05 | 2026-11-05 |
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-11-06 |
| ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma Allogeneic Hematopoietic Stem Cell Transplantation, Astatine At 211 Anti-CD38 Monoclonal Antibody OKT10-B10, Cyclophosphamide - Multiple Myeloma, Recurrent Multiple Myeloma | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2027-06-01 | 2026-09-11 | |
| Lifileucel (TIL) Therapy After PD-1 Blockade Failure in Kidney Cancer Cyclophosphamide, Fludarabine, Aldesleukin (IL-2) - Kidney Cancers, Renal Cell Carcinoma (Kidney Cancer) | Phase 2 | Not yet recruiting | Beth Israel Deaconess Medical Center | 10 | 2027-04-26 | 2026-11-09 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Aggressive T Cell Hematological Malignancies C9/CD5CAR/IL-15 NK cells, Rituximab, Fludarabine - Hematological Malignancies | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 70 | 2027-02-28 | 2026-08-20 |
| Autologous Tumor Infiltrating Lymphocytes With Interleukin-2 for the Treatment of Locally Advanced, Recurrent or Metastatic Gastrointestinal Stromal Tumors Aldesleukin, Biospecimen Collection, Chest Radiography - Locally Advanced Gastrointestinal Stromal Tumor, Metastatic Gastrointestinal Stromal Tumor | Phase 2 | Not yet recruiting | Joal Beane | 59 | 2027-02-15 | 2026-10-13 |
| A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis | Phase 3 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 92 | 2027-02-03 | 2026-09-18 |
| To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Anitocabtagene Autoleucel, Isatuximab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 750 | 2027-02-01 | 2026-10-29 |
| Metabolically Fit CD19 CAR T Cells With CD34 Selection Markers in Adults With CD19-Positive B-Cell Acute Lymphocytic Leukemia Fludarabine, Cyclophosphamide, Levetiracetam - CD19 Positive, B-ALL | Phase 1 | Not yet recruiting | Medical University of South Carolina | 18 | 2027-02-01 | 2026-11-13 |
| Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome Allogeneic CD34+-enriched and CD45RA-depleted PBSCs, Biospecimen Collection, Bone Marrow Aspiration - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Not yet recruiting | Fred Hutchinson Cancer Center | 52 | 2027-01-01 | 2026-09-14 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| US/PA/E Imaging for Early Identification of Tumor Response in Patients With Stage II-III Triple Negative Breast Cancer Receiving Neoadjuvant Immunotherapy and Chemotherapy Elastography, Magnetic Resonance Imaging, Photoacoustic Imaging - Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8 | Phase 2 | Not yet recruiting | Emory University | 32 | 2027-01-01 | 2026-11-04 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-31 | 2026-11-12 |
| Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma Biospecimen Collection, Cisplatin, Computed Tomography - Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma | Phase 1 | Not yet recruiting | National Cancer Institute (NCI) | 16 | 2026-12-30 | 2026-11-06 |
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 Surovatamig, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 3 | Not yet recruiting | AstraZeneca | 1200 | 2026-12-22 | 2026-11-02 |
| Linvoseltamab Versus Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone (Dara-Vcd) in Adult Participants With Newly Diagnosed Systemic Light Chain Amyloidosis Linvoseltamab, Daratumumab, Bortezomib - Newly Diagnosed Amyloidosis, Amyloidosis Stage I-IIIA | Phase 3 | Not yet recruiting | Regeneron Pharmaceuticals | 382 | 2026-12-18 | 2026-10-28 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
Showing 20 of 3782. Sign in to see all of them.
Breast Neoplasms (560) · Lymphoma (449) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (413) · Lymphoma, Large B-Cell, Diffuse (358) · Leukemia (347) · Multiple Myeloma (340) · Lymphoma, Non-Hodgkin (320) · Leukemia, Myeloid, Acute (293) · Leukemia, Lymphocytic, Chronic, B-Cell (286) · Lymphoma, Follicular (243) · Myelodysplastic Syndromes (226) · Burkitt Lymphoma (224) · Lymphoma, Mantle-Cell (204) · Hodgkin Disease (193) · Recurrence (170)
National Cancer Institute (NCI) (215) · M.D. Anderson Cancer Center (174) · Children's Oncology Group (100) · Fred Hutchinson Cancer Center (92) · Masonic Cancer Center, University of Minnesota (80) · Memorial Sloan Kettering Cancer Center (80) · St. Jude Children's Research Hospital (72) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (70) · City of Hope Medical Center (60) · Hoffmann-La Roche (53) · SWOG Cancer Research Network (39) · Mayo Clinic (34) · Dana-Farber Cancer Institute (33) · Kite, A Gilead Company (33) · Baylor College of Medicine (32)
United States (2260) · China (545) · Canada (315) · Germany (269) · France (254) · United Kingdom (251) · Australia (235) · Italy (232) · Spain (215) · Netherlands (151) · Belgium (148) · Switzerland (130) · Poland (111) · South Korea (111) · Puerto Rico (101)
Steven A Rosenberg, M.D. (28) · Norman Wolmark, MD (15) · Richard Burt, MD (11) · Qifa Liu (10) · James N Kochenderfer, M.D. (9)
PMID 34515338, PMID 41671463, PMID 37505794, PMID 40135712, PMID 40207789, PMID 34037241, PMID 39121442, PMID 22555974, PMID 31221778, PMID 31401903, PMID 32450725, PMID 33357481, PMID 36240296, PMID 39319495, PMID 22508812, PMID 22689675, PMID 27282998, PMID 27641687, PMID 29567784, PMID 33242441, PMID 35622074, PMID 37890117, PMID 38603649, PMID 38979716, PMID 40501401, PMID 12171484, PMID 18997171, PMID 21403127, PMID 22430088, PMID 23007406, PMID 23861247, PMID 24970932, PMID 25310303, PMID 25628469, PMID 26101239, PMID 26373676, PMID 30714987, PMID 32747469, PMID 34252375, PMID 34778952, PMID 34870327, PMID 35882475, PMID 38335467, PMID 38446568, PMID 39058968, PMID 42133908, PMID 16105981, PMID 16236738, PMID 16421426, PMID 16790698
U10CA098543 (54), U10CA180886 (54), P30CA033572 (41), U10CA032102 (38), P30CA015704 (30), 2023 (27), P30CA006973 (27), 2016 (23), 2015 (20), P30CA043703 (20), U10CA031946 (20), P30CA015083 (18), P30CA016672 (18), 2017 (17), 2019 (17)